☆ 4.8 Editorial Material

Advancing immunotherapy for early-stage triple-negative breast cancer

LANCET (2020)

期刊

LANCET

卷 396, 期 10257, 页码 1046-1048

出版社

ELSEVIER SCIENCE INC

DOI: 10.1016/S0140-6736(20)31962-0

关键词

-

类别

Medicine, General & Internal

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Advances in the Management of Early-Stage Triple-Negative Breast Cancer

Prarthna V. Bhardwaj, Yue Wang, Elizabeth Brunk, Philip M. Spanheimer, Yara G. Abdou

Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with heterogeneous characteristics. Neoadjuvant therapy (NAT) is the preferred treatment for early-stage TNBC as it downstages tumors, monitors treatment response, and provides important prognostic information. The use of immune checkpoint inhibitors and targeted agents has revolutionized TNBC treatment, but identifying the subgroups that benefit most from these therapies is still under investigation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Immunotherapy for Triple-Negative Breast Cancer

Yifeng Cao, Chuyang Chen, Yi Tao, Weifeng Lin, Ping Wang

Summary: Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, leading to increased mortality of patients due to accelerated aggressiveness and terrible metastasis. Hindered by the negative expression of certain receptors, targeted therapy has been challenging, but the higher immune response in TNBC compared to other breast cancer types makes it suitable for immunotherapy.

PHARMACEUTICS (2021)

添加到收藏夹

Review Oncology

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies

Nour Abuhadra, Shane Stecklein, Priyanka Sharma, Stacy Moulder

Summary: This article discusses the development of a measurement tool for assessing symptoms in advanced non-small cell lung cancer (NSCLC) and the challenges in personalizing therapy for triple-negative breast cancer (TNBC). Despite high response rates in some TNBC patients, personalized treatment strategies are limited due to the scarcity of options and predictive biomarkers. Recent advances in understanding TNBC biology have sparked interest in optimizing treatment and personalizing therapy to achieve better outcomes.

ONCOLOGIST (2022)

添加到收藏夹

Review Health Care Sciences & Services

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

Tinglin Yang, Wenhui Li, Tao Huang, Jun Zhou

Summary: The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought drastic changes to antitumor therapy. PD-1 and PD-L1 are promising targets that can encourage the immune system to eliminate cancer cells. Integrating PD-1/PD-L1 inhibitors into existing treatments for early-stage triple-negative breast cancer (TNBC) has attracted attention. This article summarizes the clinical benefit of PD-1/PD-L1 inhibitors in combination with neoadjuvant chemotherapy, adjuvant chemotherapy, and targeted therapy for early-stage TNBC. The potential biomarkers, immune-related adverse events (irAEs), and challenges in TNBC anti-PD-1/PD-L1 therapy are also discussed. Ongoing studies in immunotherapy and the significant clinical prospects of PD-1/PD-L1 inhibitors in early-stage TNBC are highlighted. Further research is necessary to overcome the challenges and maximize the efficacy of anti-PD-1/PD-L1 therapy in TNBC.

JOURNAL OF PERSONALIZED MEDICINE (2023)

添加到收藏夹

Review Medicine, General & Internal

Theranostics for Triple-Negative Breast Cancer

Hyeryeon Choi, Kwangsoon Kim

Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Current treatment options are limited and variable response to chemotherapy exists due to disease heterogeneity. This review discusses FDA-approved targeted therapies for TNBC, as well as novel theranostic approaches using nanocarriers. These approaches aim to improve diagnosis and treatment of TNBC by enabling targeted drug delivery and visualization of the lesion.

DIAGNOSTICS (2023)

添加到收藏夹

Review Oncology

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Iris Nederlof, Leonie Voorwerk, Marleen Kok

Summary: A significant proportion of early-stage triple-negative breast cancer patients have high levels of tumor-infiltrating lymphocytes, indicating a strong endogenous immune response against cancer. Immune-checkpoint inhibition combined with chemotherapy has become the standard of care for these patients. Future challenges include identifying which patients can be treated with immune-checkpoint inhibition alone or with reduced chemotherapy, determining the optimal duration of treatment, and finding biomarkers for treatment response prediction. For patients who do not respond effectively to current treatment, developing new immunomodulatory therapies and response-guided neoadjuvant approaches are needed.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Nanoscience & Nanotechnology

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer

Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing

Summary: Chemoimmunotherapy shows promise for treating TNBC, but challenges remain in improving efficacy and reducing side effects.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2022)

添加到收藏夹

Article Cell Biology

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer

Fangfang Duan, Muyi Zhong, Jinhui Ye, Li Wang, Chang Jiang, Zhongyu Yuan, Xiwen Bi, Jiajia Huang

Summary: This study explored the prognostic value of a novel comprehensive biomarker, the iron-monocyte-to-lymphocyte ratio (IronMLR) score, in patients with early-stage triple-negative breast cancer (TNBC). The study found that the IronMLR score was an independent predictor of disease-free survival (DFS) and overall survival (OS) in early-stage TNBC patients. A prognostic nomogram integrating the IronMLR score, T stage, and N stage was established to improve individualized survival predictions.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

添加到收藏夹

Letter Medicine, General & Internal

Pembrolizumab in Early Triple-Negative Breast Cancer

Shuvadeep Ganguly, Ajay Gogia

Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Chemistry, Medicinal

Immunotherapy Treatment for Triple Negative Breast Cancer

Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, Mehra Golshan, Rachel A. Greenup, Nita Ahuja

Summary: Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes in breast cancer with dismal prognosis, lacking targeted therapy options. Immunotherapy, particularly immune checkpoint inhibitor therapy, has revolutionized the treatment landscape for TNBC, showing promising results.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Advances in immunotherapy for triple-negative breast cancer

Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu

Summary: Immunotherapy has emerged as a promising strategy for treating triple-negative breast cancer (TNBC), which stimulates the immune system to kill tumor cells and offers new hope for patients. Breakthroughs in immune checkpoint inhibitors (ICIs) have led to individualized immunotherapy schedules and the combination with other treatment methods to overcome drug resistance.

MOLECULAR CANCER (2023)

添加到收藏夹

Article Oncology

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Renato Brito Baleeiro, Peng Liu, Louisa S. Chard Dunmall, Carmela Di Gioia, Ai Nagano, Lauren Cutmore, Jun Wang, Claude Chelala, Lydon Wainaina Nyambura, Peter Walden, Nicholas Lemoine, Yaohe Wang

Summary: This study successfully identified immunogenic neoantigens and generated neoantigen-specific CD8+T cells capable of recognizing human triple-negative breast cancer cells. Using an oncolytic virus as a delivery system, the researchers demonstrated that vaccination with neoantigens can induce a specific CD8+T cell response, slow tumor growth, and increase survival in a mouse model of TNBC. This study provides a promising approach for the development of neoantigen-based immunotherapies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Oncology

Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy

Elizabeth A. Mittendorf, Olga Kantor, Anna Weiss, Edward Richardson, Ana Garrido-Castro, Leah H. Portnow, Ian E. Krop, Nancy U. Lin, Eric P. Winer, Sara M. Tolaney, Tari A. King

Summary: This study evaluates the nodal positivity rates in TNBC patients and examines the utility of axillary ultrasound and biopsy in the setting of a negative clinical examination. The results show that more than 10% of cT1cN0 and over 20% of cT2N0 TNBC patients have pathologic node-positive disease. Axillary ultrasound can be used to identify patients with a normal clinical examination who should consider preoperative pembrolizumab.

ANNALS OF SURGICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Summary: Triple-negative breast cancer is the most aggressive subtype of breast cancer, where chemotherapy shows activity in some patients but drug resistance remains a challenge. Significant progress in genetic analysis has led to the identification of novel targets and improved precision in therapeutic interventions, advancing treatment strategies.

FRONTIERS OF MEDICINE (2021)

添加到收藏夹

Review Oncology

Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?

Ravi Kumar Gupta, Arya Mariam Roy, Ashish Gupta, Kazuaki Takabe, Ajay Dhakal, Mateusz Opyrchal, Pawel Kalinski, Shipra Gandhi

Summary: This article summarizes emerging opportunities to use less toxic therapies in early-stage triple-negative breast cancer (TNBC), providing a personalized approach for patients. It reviews completed and ongoing clinical trials and provides guidance on stratifying patients to maximize benefits without unnecessary toxicities.

CANCERS (2022)

添加到收藏夹

Article Oncology

High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer

Massimiliano Gennaro, Elisabetta Meneghini, Paolo Baili, Sara Bravaccini, Annalisa Curcio, Maria Carmen De Santis, Laura Lozza, Chiara Listorti, Serena Di Cosimo, Milena Sant, Secondo Folli

TUMORI JOURNAL (2020)

添加到收藏夹

Review Oncology

The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells

Carolina Reduzzi, Marta Vismara, Lorenzo Gerratana, Marco Silvestri, Filippo De Braud, Francesco Raspagliesi, Elena Verzoni, Serena Di Cosimo, Laura D. Locati, Massimo Cristofanilli, Maria Grazia Daidone, Vera Cappelletti

SEMINARS IN CANCER BIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Marco Silvestri, Jose Baselga, Martine Piccart, Jens Huober, Miguel Izquierdo, Lorena de la Pena, Florentine S. Hilbers, Evandro de Azambuja, Michael Untch, Lajos Pusztai, Kathleen Pritchard, Paolo Nuciforo, Anne Vincent-Salomon, Fraser Symmans, Giovanni Apolone, Filippo G. de Braud, Marilena Iorio, Paolo Verderio, Maria Grazia Daidone

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Meeting Abstract Oncology

Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials

M. A. Franzoi, L. Ameye, D. Eiger, M. Piccart, M. D. R. A. Brandao, N. Ponde, C. Desmedt, S. Di Cosimo, M. Paesmans, R. Caparica, N. Kotecki, M. Lambertini, C. De Angelis, A. H. Awada, E. de Azambuja

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Automated breast ultrasound compared to hand-held ultrasound in surveillance after breast-conserving surgery

Catherine Depretto, Alessandro Liguori, Alessandra Primolevo, Serena Di Cosimo, Francesco Cartia, Claudio Ferranti, Gianfranco P. Scaperrotta

Summary: The study found a substantial agreement between automated breast ultrasound (ABUS) and hand-held ultrasound (HHUS) in surveillance of women with a history of breast cancer. ABUS recognized all cancers detected by HHUS and could potentially play a role in first-level surveillance of women at intermediate risk.

TUMORI JOURNAL (2021)

添加到收藏夹

Article Oncology

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

Serena Di Cosimo, Luca Porcu, Fatima Cardoso

Summary: Cell-cycle abnormalities are common in HR+/HER2- breast cancer, where CDK 4/6 inhibitors have been proven effective in combination with endocrine therapy. More research is needed to further explore the efficacy and toxicity of adjuvant combined therapy in early breast cancer patients.

BREAST (2021)

添加到收藏夹

Article Oncology

Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study

Serena Di Cosimo, Barbara Tagliaferri, Daniele Generali, Fabiola Giudici, Francesco Agustoni, Antonio Bernardo, Karen Borgonovo, Gabriella Farina, Giovanna Luchena, Andrea Luciani, Franco Nole, Laura Palmeri, Filippo Pietrantonio, Guido Poggi, Paolo Andrea Zucali, Emanuela Balletti, Giovanna Catania, Ottavia Bernocchi, Federica D'Antonio, Monica Giordano, Francesco Grossi, Angioletta Lasagna, Nicla La Verde, Mariangela Manzoni, Benedetta Montagna, Angelo Olgiati, Alessandra Raimondi, Irene Rampinelli, Elena Verri, Alberto Zaniboni, Massimo Di Maio, Giordano Beretta, Marco Danova

Summary: The AIOM-L Corona study assessed prognostic factors associated with outcomes in 231 cancer patients infected by SARS-CoV-2 in Lombardy. Risk factors for mortality in COVID-19 were significant, with metastatic patients receiving active therapy less likely to die. During the pandemic, cancer patients should avoid exposure to SARS-CoV-2 and consider treatment adjustments and vaccination.

CANCERS (2021)

添加到收藏夹

Article Oncology

Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer

Carolina Reduzzi, Serena Di Cosimo, Lorenzo Gerratana, Rosita Motta, Antonia Martinetti, Andrea Vingiani, Paolo D'Amico, Youbin Zhang, Marta Vismara, Catherine Depretto, Gianfranco Scaperrotta, Secondo Folli, Giancarlo Pruneri, Massimo Cristofanilli, Maria Grazia Daidone, Vera Cappelletti

Summary: The majority of breast cancer-related deaths are caused by metastases, which are believed to originate from circulating tumor cells (CTCs), particularly CTC-clusters. Current conventional technology limits the early-stage analysis of CTCs, but a marker-independent blood filtration method has shown promise in detecting a high number of CTC-clusters in stage II-III breast cancer patients. This suggests that CTC-clusters may be an early event in the natural history of breast cancer, with marker-independent approaches improving their detection rates.

CANCERS (2021)

添加到收藏夹

Article Oncology

Nobody dares stopping clinical research, not even COVID-19

Andrea Malfettone, Serena Di Cosimo, Jose Manuel Perez-Garcia, Alicia Garcia, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortes

Summary: In the global health emergency of COVID-19, clinical trial management is crucial for the pharmaceutical industry, sponsors, and healthcare professionals. Data from managing interventional oncology clinical studies emphasize the importance of prioritizing patient safety and data validity, and adopting measures such as telemedicine and remote monitoring, which have been essential for successful adaptations to ensure ongoing clinical cancer research.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial

Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young-Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling-Ming Tseng, Mei-Ching Liu, Begona Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de la Haba-Rodriguez, Do-Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue

Summary: In HER2-positive/ER-positive breast cancer, the 41-gene classifier TRAR has been identified as an independent predictor of pCR, serving as a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist in treatment escalation and de-escalation strategies.

MOLECULAR ONCOLOGY (2022)

添加到收藏夹

Article Oncology

COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020

Annalisa Trama, Alice Bernasconi, Laura Botta, Serena Di Cosimo, Rosalba Miceli, Melanie Claps, Fabio Badenchini, Roberto Lillini, Massimiliano Rubino, Paolo Lasalvia

Summary: The study aimed to analyze the year-long decline in cancer diagnoses in the Lombardy region of Italy on a population level, and characterize the tumors with the greatest reduction by patient age, sex, and tumor stage at diagnosis. Using healthcare utilization databases, the study compared the frequency of new cancer diagnoses in 2019 and 2020, observed two peaks in the decline, and found that diagnoses of common cancers remained below pre-pandemic levels. The study emphasized the importance of timely monitoring and interventions to prevent disruptions in diagnostic services for cancer patients during emergencies.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Lorenzo Castagnoli, Matteo Dugo, Barbara Galbardi, Roberto Salgado, Sherene Loi, Stefan Michiels, Tiziana Triulzi, Elda Tagliabue, Sarra El-Abed, Miguel Izquierdo, Evandro de Azambuja, Paolo Nuciforo, Jens Huober, Luca Moscetti, Wolfgang Janni, Maria Antonia Coccia-Portugal, Paola Antonia Corsetto, Antonino Belfiore, Daniele Lorenzini, Maria Grazia Daidone, Andrea Vingiani, Luca Gianni, Serenella Maria Pupa, Giampaolo Bianchini, Giancarlo Pruneri, Claudio Vernieri

Summary: This study found that high expression of CD36 is associated with worse clinical outcomes in early-stage HER2+ BC patients treated with anti-HER2 therapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Review Oncology

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective

Valentina Fogazzi, Marcel Kapahnke, Alessandra Cataldo, Ilaria Plantamura, Elda Tagliabue, Serena Di Cosimo, Giulia Cosentino, Marilena V. Iorio

Summary: Breast cancer is the most commonly diagnosed malignancy in women globally, with 20% of cases being HER2 positive. Despite the improvement in prognosis with anti-HER2 agents, a significant number of patients do not respond to treatment. MicroRNAs are promising clinical tools for managing HER2 positive breast cancers due to their detectability and stability in tissues and blood, as well as their potential as therapeutic agents, prognostic and predictive biomarkers.

CANCERS (2022)

添加到收藏夹

Article Oncology

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma

Marco Silvestri, Trung Nghia Vu, Federico Nichetti, Monica Niger, Serena Di Cosimo, Filippo De Braud, Giancarlo Pruneri, Yudi Pawitan, Stefano Calza, Vera Cappelletti

Summary: This study aimed to provide a gene expression-based classification of extrahepatic and intrahepatic cholangiocarcinoma by collecting all available public records. Through unsupervised clustering analysis of gene expression data, four subgroups characterized by different immune infiltrate and signaling pathways were identified in both ICC and ECC. Class predictors were developed using short gene list signatures and subgroups of ICC tumors with different prognosis were identified in an independent dataset.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients

Serena Di Cosimo, Silva Ljevar, Annalisa Trama, Alice Bernasconi, Paolo Lasalvia, Maria Carmen De Santis, Vera Cappelletti, Rosalba Miceli, Giovanni Apolone

Summary: We examined the impact of COVID-19 on newly-diagnosed breast cancer patients. There were two significant drops in diagnoses in 2020 compared to 2019. Several treatment measures, such as surgery, chemotherapy, and radiotherapy, decreased in 2020. COVID-19 occurrence was associated with increased mortality. The findings highlight the importance of continuity of care and the need to minimize treatment delays in breast cancer patients.

BREAST (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.